Beam raises $500M in an equity financing

Beam Therapeutics

Beam priced an underwritten offering of common stock and pre-funded warrants at $28.48 per share (with warrants), raising about $500 million gross. The financing, announced the same day as positive BEAM-302 data, funds the base-editing pipeline and a potential pivotal trial.

• Gross proceeds: $500 million from registered direct offering.
• Proceeds: funding base-editing pipeline including potential BEAM-302 pivotal trial.
• Cash position after offering: $1.2 billion as of March 31, 2025.
• Runway extended into 2028.